{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"I-MAB"},"Symbol":{"label":"Symbol","value":"IMAB"},"Address":{"label":"Address","value":"555 WEST HAIYANG ROAD,55TH - 56TH FLOOR, NEW BUND CENTER, SHANGHAI, 200124, China"},"Phone":{"label":"Phone","value":"+86 2160578000"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Asia"},"CompanyDescription":{"label":"Company Description","value":"I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia."},"CompanyUrl":{"label":"Company Url","value":"https://www.i-mabbiopharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jerry Wang","title":"Chief Scientific Officer"},{"name":"Phillip Dennis","title":"Chief Medical Officer"},{"name":"Xi-Yong Fu","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}